At WHOOP, we're on a mission to unlock human performance. WHOOP empowers its members to perform at a high level by providing a deep understanding of the interactions between their unique physiology and chosen behaviors.

As a Program Manager at WHOOP, you will be a critical member of the team that develops the next generation of models that will power the features we can provide to members. This role sits at the intersection of machine learning, data science, sensor intelligence, platform engineering, and product, and is responsible for translating complex technical work into clear plans, dependencies, and outcomes to ensure projects are delivered on time, aligned to strategy, and built for scale.

Success in this role will require a high degree of adaptability and a solutions mindset, ability to simplify complexity, while continuously managing shifting priorities.

Foundation AI capabilities are critical to our ability to innovate quickly and responsibly. This role ensures that the underlying systems powering our features are delivered thoughtfully, reliably, and in a way that unlocks impact across the entire organization.

RESPONSIBILITIES:

Drive Foundation AI projects from kickoff through development to deployment and stabilization
Support the VP of Foundation AI to translate strategy into executable roadmaps with clear milestones, risks, dependencies, and success metrics
Develop project plans consistent with business goals and requirements for algorithm performance
Establish and maintain program governance, including planning cadences, status reporting, decision forums, and executive communication
Work with the FAI team, Data Science, Sensor Intelligence, WHOOP Labs, Data Engineering, Software, Firmware to ensure project objectives and priorities are aligned across departments
Bring together key stakeholders to facilitate timely and lasting decision-making
Partner with the extended team on compute infrastructure planning, focusing on availability constraints, capacity forecasting, vendor quotes/lead times, and tradeoffs across vendors.
Partner with the broader RAD program management team to continuously improve the development process to enable execution of projects in an organized, methodical, and predictable manner.
Identify and manage project risks and issues, ensuring mitigations are in place to reduce potential impacts.
Facilitate cross-functional communication across WHOOP for awareness and understanding.
Understanding of technical issues to facilitate resolution of project blockers is a plus

QUALIFICATIONS:

2+ years of industry experience in program or project management, preferably involving AI/ML, data platforms or large-scale systems
Experience working with AI or applied ML teams
Familiarity with agile methodologies, sprint planning, backlog grooming processes
Data-driven approach to strategic planning, comfortable reviewing metrics and identifying ways to measure program success
Familiarity with AI/ML concepts (e.g., model training, inference, data pipelines, evaluation, experimentation), hands-on coding experience is not required
Clear, confident communicator who can bridge deeply technical teams and business stakeholders
Proven ability to influence without authority and drive alignment across diverse teams
Nice to Have:
- Experience working with research teams
- Background in consumer technology, platforms, or data-driven products
- Experience organizing projects using Jira or similar platforms

This role is based in the WHOOP office located in Boston, MA. The successful candidate must be prepared to relocate if necessary to work out of the Boston, MA office.

Interested in the role, but don’t meet every qualification? We encourage you to still apply! At WHOOP, we believe there is much more to a candidate than what is written on paper, and we value character as much as experience. As we continue to build a diverse and inclusive environment, we encourage anyone who is interested in this role to apply.

WHOOP is an Equal Opportunity Employer and participates in E-verify to determine employment eligibility. It is unlawful in Massachusetts to require or administer a lie detector test as a condition of employment or continued employment. An employer who violates this law shall be subject to criminal penalties and civil liability.

At WHOOP, we view total compensation as the combination of base salary, equity, and benefits, with equity serving as a key differentiator that aligns our employees with the long-term success of the company and allows every member of our corporate team to own part of WHOOP and share in the company’s long-term growth and success.

The U.S. base salary range for this full-time position is $$125,000-$175,000 Salary ranges are determined by role, level, and location. Within each range, individual pay is based on factors such as job-related skills, experience, performance, and relevant education or training.

In addition to the base salary, the successful candidate will also receive benefits and a generous equity package.

These ranges may be modified in the future to reflect evolving market conditions and organizational needs. While most offers will typically fall toward the starting point of the range, total compensation will depend on the candidate’s specific qualifications, expertise, and alignment with the role’s requirements.

Learn more about WHOOP.

About the company

Whoop makes a screenless wristband that tracks sleep, exercise strain, and recovery around the clock, and it sells the band to athletes and everyday users only as part of a membership. In 2020, the PGA Tour gave Whoop straps to players and caddies after one golfer's data flagged his COVID-19 infection before he had symptoms. The band records heart rate, the variation between beats, skin temperature, and blood oxygen, and the app turns those readings into daily scores and advice on when to push or rest. Members pay a yearly fee that covers the band, with pricier tiers adding heart-rhythm and blood pressure readings, and Whoop also sells blood tests. Whoop was founded in 2012 at Harvard's startup lab and is based in Boston.

Company Size

1,001-5,000

Company Stage

Series G

Total Funding

$979.8M

Headquarters

Boston, Massachusetts

Founded

2012

Get referred to Whoop

See people who can refer or advise you

Simplify's Take

What believers are saying

Growth pays for itself: Whoop's yearly sales pace doubled to $1.1 billion by December 2025, with positive cash flow.
Equity has a path to cash: in August 2026, Whoop's CEO put its IPO about 18 months away.
Fast hiring widens scope: Whoop made almost 400 of its 600 planned hires by August 2026, on an 800-person base.

What critics are saying

Big Tech is undercutting it: Google's $99.99 Fitbit Air, launched May 2026, needs no subscription; Whoop's starts at $199 yearly.
Cashing out isn't guaranteed: larger smart-ring rival Oura shelved its $2.2 billion IPO in September 2026, citing market uncertainty.
Plan to live near Boston: 155 of Whoop's 158 open roles in October 2026 are on-site at its headquarters there.

What makes Whoop unique

Medical giants are part-owners: glucose-monitor maker Abbott and the Mayo Clinic invested in Whoop's March 2026 round.
Copying its look draws lawsuits: a federal judge halted US sales of a near-identical Chinese band in February 2026.
Star athletes are owners, not just endorsers: Cristiano Ronaldo, LeBron James and Rory McIlroy invested in its March 2026 round.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Take Time Off: Time outside of the office is important for sleep, strain and recovery! Our PTO plan encourages members to take time off in order to come back refreshed.
Live a Healthy Lifestyle: Our competitive benefits package includes premium medical, dental, and vision coverage for employees and their dependents. Life and disability insurance are also available.
Feel Invested: In addition to a competitive base salary and 401k, you're eligible to receive stock options to share in the future of WHOOP. Work means more when you have personal stake. You have ownership in what we are building.
Eat Well: Keep hunger at bay with endless snacks in our fully stocked kitchen. Enjoy catered team lunches on Friday, and even a cold brew keg.
Know The Product: We want you to understand and experience the product firsthand. We offer you a WHOOP strap and membership at no cost.
Be Active: Take advantage of our office gym and on-site showers! WHOOP also offers a $500 yearly wellness perk for fitness classes and memberships.
Be Present: It's important to be present when bringing home a new family member. Take care of your loved ones with 12 weeks paid parental leave, plus an additional 2 weeks to gradually return to work.
Love Where You Work: Sitting in the heart of Fenway, our beautiful office overlooks Fenway Park. A prime location for great food, not to mention catching a Sox game, too!
Work Hard, Play Harder: If we don't already have a club here that fits your lifestyle and interests, you're encouraged to start one. Share your passions with others at work, or discover new ones!

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Abu Dhabi Media Office

Oct 21st, 2026

In the presence of Theyab bin Mohamed bin Zayed, Department of Health - Abu Dhabi signs agreements to advance research in life sciences, personalised preventive health, and AI drug discovery.

In the presence of Theyab bin Mohamed bin Zayed, Department of Health - Abu Dhabi signs agreements to advance research in life sciences, personalised preventive health, and AI drug discovery. In the presence of His Highness Sheikh Theyab bin Mohamed bin Zayed Al Nahyan, Deputy Chairman of the Presidential Court for Development and Fallen Heroes' Affairs, the Department of Health - Abu Dhabi (DoH) has signed agreements with Isomorphic Labs, WHOOP, and Cleveland Clinic Abu Dhabi, and AstraZeneca. DoH and Isomorphic Labs announced the signing of an agreement to collaborate on AI-enabled drug discovery research and explore innovation frameworks for pre-clinical research. The agreement was signed at the Abu Dhabi Future Health Summit by Her Excellency Dr Noura Khamis Al Ghaithi, Undersecretary of the Department of Health - Abu Dhabi, and Max Jaderberg, President of Isomorphic Labs. Under the agreement, the collaboration aims to develop a pre-clinical research roadmap for selected AI-enabled discovery projects over a 24-month period, with research conducted within Abu Dhabi's Trusted Research Environment. Isomorphic Labs has built a world-leading drug design engine (IsoDDE) comprised of foundational AI models to provide the predictive fidelity required to navigate novel biological systems with unprecedented accuracy. His Excellency Mansoor Ibrahim Al Mansoori, said: "Artificial intelligence is changing not only how quickly we discover new medicines, but how precisely we can target disease. Realising that potential requires more than technology. It requires rich clinical and genomic data, a research environment that can translate insight into discovery, and regulation that advances at the pace of science. "Abu Dhabi has built that foundation. Through the Emirati Genome Programme and our connected health system, we are opening new possibilities for more precise, personalised treatments. Our collaboration with Isomorphic Labs brings together expertise in AI drug discovery and Abu Dhabi's unique strengths to accelerate the development of treatments that can benefit patients here and globally." Mr Jaderberg said: "At Isomorphic Labs, we are reimagining the entire drug discovery process from first principles with AI. The collaboration marks a critical step forward in advancing AI-driven drug discovery. We have a shared commitment to scientific innovation, with the ultimate aim of accelerating delivery of medicines to patients globally." The collaboration reflects DoH's role in enabling the responsible use of predictive and generative AI in health research. It forms part of Abu Dhabi's intelligent life sciences strategy which connects population-scale genomic and health data, research infrastructure, and regulatory pathways to accelerate the development of new medicines in the emirate. Together, the parties aim to help accelerate AI-driven discovery research, as well as broaden the evidence base for future medicines, as Middle Eastern populations have been historically underrepresented in the genomic data behind drug discovery. Meanwhile, DoH and WHOOP announced a strategic research collaboration to explore the role of continuous health insights and coaching in preventive health. The research supports Abu Dhabi's shift from reacting to illness towards personalised prevention at scale. The agreement was also signed at the Abu Dhabi Future Health Summit 2026 by His Excellency Mansoor Ibrahim Al Mansoori, and Will Ahmed, Founder and CEO of WHOOP. The collaboration will consist of a phased research programme on heart and metabolic health, exploring how wearable technology can help people better understand their bodies and take a more informed, proactive approach to their health. WHOOP continuously senses an individual's key health indicators such as sleep, recovery, strain, stress, and cardiovascular health, providing context beyond a single measurement. The first, foundational study of the24-month programme aims to assess how this continuous data, alongside coaching from WHOOP, can affect key health markers like weight, waist circumference, heart rate, blood pressure, cholesterol, blood sugar, and sleep over a six-month period for adults with obesity and high blood pressure. The study's design and oversight will be supported by physicians in Abu Dhabi. Subsequent studies will explore how WHOOP can help reduce risk factors for heart and metabolic disease by supporting the behavioural changes required alongside treatment. The programme will generate novel, real-world evidence on the role wearable technology can play in preventive and cardiometabolic health. In line with Abu Dhabi's prevention-led health agenda, the collaboration brings the continuous health data of WHOOP into the emirate's intelligent health system to accelerate population health research and safely scale new models of care. His Excellency Mansoor Ibrahim Al Mansoori said: "Our bodies can signal changes long before we feel unwell. The earlier we recognise those signals, the more we can do to protect our health. Abu Dhabi has built an intelligent health system that uses AI to turn complex health data into meaningful, personalised insights. Our partnership with WHOOP will explore how data from wearables can be translated into practical, personalised guidance, helping people better understand their health and make lasting changes." Mr Ahmed said: "This is a landmark partnership for WHOOP and Abu Dhabi. We first began working in the UAE in 2016. Since then, hundreds of thousands of citizens and residents have come to trust WHOOP to support their health and performance goals. At WHOOP, we believe deeply in what continuous data insights and coaching can offer when applied to real health challenges. Abu Dhabi puts data at the heart of how it cares for people, and I'm incredibly proud to work alongside them to explore what's possible, and even more excited about what we can accomplish together." Research will follow data governance guidelines over data minimisation, transparent data processing and secure storage, in line with applicable regulations and international best practices. Meanwhile, DoH, Cleveland Clinic Abu Dhabi, and AstraZeneca have announced a new collaboration positioning Abu Dhabi as a priority location in AstraZeneca's global clinical trial network. The collaboration leverages the emirate's intelligent health system, advanced research infrastructure and enabling regulatory environment. The collaboration will explore the feasibility of up to 30 clinical trials in Abu Dhabi by 2030 across AstraZeneca's biopharmaceutical portfolio with a focus on cardiovascular, renal and metabolic (CVRM) diseases, which are leading causes of mortality in UAE. The collaboration could deliver an estimated AED180 million (US$50 million) investment into life sciences research in Abu Dhabi by 2030. The collaboration builds on Abu Dhabi's long-term partnership with AstraZeneca in research, genomics, and digital health. It brings together DoH's role in enabling clinical research and developing Abu Dhabi's intelligent life sciences ecosystem, Cleveland Clinic Abu Dhabi's clinical and research expertise, and AstraZeneca's global R&D capabilities. Drawing on Cleveland Clinic Abu Dhabi's research infrastructure, it aims to strengthen local research capacity and generate high-quality evidence relevant to the region's health needs. The first six trials are expected to begin at Cleveland Clinic Abu Dhabi by the end of 2026. His Excellency Mansoor Ibrahim Al Mansoori, said: "Abu Dhabi has built an intelligent health system where population scale data, research infrastructure, and clinical excellence translate into better health outcomes. This collaboration brings global clinical trials into this system, supporting our ambition to create a globally recognised environment for clinical research, and strengthens the evidence base to help ensure that new medicines are developed for the diversity of the world's patients." Dr Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said: "By combining Cleveland Clinic clinical expertise, the Department of Health - Abu Dhabi's infrastructure, and AstraZeneca's global research capabilities, we can accelerate clinical research, expand access to innovative treatments, and generate evidence that improves patient outcomes. Together, we are strengthening Abu Dhabi's position as a leader in clinical research, with benefits for patients across the globe." Mikhail Kosiborod, Senior Vice President, Late CVRM BioPharmaceutical R&D, AstraZeneca, said: "Clinical trials play a vital role in generating high-quality evidence that advances healthcare, providing patients with early access to promising new therapies and ensuring our data is generated in diverse, representative populations. This collaboration with the Department of Health - Abu Dhabi and Cleveland Clinic will enable further investment in clinical research infrastructure, and deliver evidence that informs clinical practice, ultimately shaping the future of patient care across conditions that are the biggest public health threats, both locally and globally." The collaboration also aims to generate locally relevant evidence, drawing on Abu Dhabi's population-scale health and genomics data to help address the historical underrepresentation of regional populations in pharmaceutical research. The proposed studies will support the development of local investigators and research professionals, while creating opportunities for eligible patients to participate in international clinical research, subject to study approvals and enrolment criteria.

exchange4media

Oct 16th, 2026

Nojoud Radwan takes on Senior Marketing Lead - GCC role at WHOOP.

Nojoud Radwan takes on Senior Marketing Lead - GCC role at WHOOP. Radwan was earlier with adidas as Senior Marketing Manager in Saudi Arabia. WHOOP has appointed Nojoud Radwan as Senior Marketing Lead - GCC, following her stint at adidas, where she led marketing strategy in Saudi Arabia. At adidas, she served as Senior Marketing Manager from August 2024 to August 2026, overseeing integrated marketing across digital, retail and influencer channels. Her responsibilities included localising global campaigns for Saudi Arabia, aligning brand narratives with local culture and youth trends, and driving creator-led activations. Before adidas, Radwan spent over six years at Nestlé in roles spanning digital marketing, social media and influencer strategy. As Digital Marketing Manager for Nestlé Purina Petcare and Nestlé Health Science from July 2023 to May 2024, she led regional digital strategy across 19 markets, focusing on e-commerce adoption, performance marketing and brand consistency. Radwan began her tenure at The Coca-Cola Company in September 2013 as Assistant Brand Manager.

Absolute Geeks

Oct 13th, 2026

WHOOP launches Arabic app as GCC membership jumps over 75%.

WHOOP launches Arabic app as GCC membership jumps over 75%. 3 hours ago WHOOP is now speaking Arabic. The subscription-based fitness wearable has rolled out a fully redesigned Arabic version of its app, allowing members to read their sleep, recovery, strain and health data in their native language for the first time, backed by a billboard and digital campaign running across the GCC. On paper, translating an app sounds like a modest update. In practice, Arabic localisation is more involved than swapping text strings. Right-to-left layouts, data-heavy dashboards and health terminology all need rethinking, which is why the company is calling this a redesign rather than a language toggle. For a product whose entire value lies in explaining complex physiological metrics like heart rate variability and recovery scores, comprehension matters more than it does for a typical consumer app. The timing reflects how important the region has become to the Boston-based company. WHOOP says GCC membership has grown by more than 75 percent year on year, and it has steadily built a physical presence here, including a dedicated UAE office and an expanding retail footprint. Later this year, WHOOP Qatar is set to open the company's first performance research and development facility outside its Boston headquarters, which could give it region-specific data on how heat, fasting and local lifestyles affect sleep and recovery. There's also a strategic investor behind the push. Abu Dhabi's Mubadala Investment Company backed WHOOP's Series G round, and the Arabic launch fulfils one of the commitments outlined in that partnership. Add sponsorship deals with UAE Team Emirates-XRG and Al Nassr, plus ties to the Dubai Fitness Challenge and the Doha Marathon, and WHOOP's regional strategy looks less like a marketing exercise and more like a long-term bet. The hardware itself is unchanged. The current band offers up to 14 days of battery life, an FDA-cleared ECG, a Healthspan longevity feature, Blood Pressure Insights and optional Advanced Labs blood testing. Blood pressure tracking remains its most contested feature after drawing an FDA warning letter in 2025 over how it was marketed.

TelecomTalk

Oct 3rd, 2026

Apple, Fitbit, whoop, Pebble: fitness trackers compared.

Apple, Fitbit, whoop, Pebble: fitness trackers compared. The screenless fitness-tracker market in India is no longer limited to WHOOP and Fitbit. Amazfit, Noise, Pebble and Garmin now offer alternatives across different price points, while Apple Watch remains a broader smartwatch option. Apple is also reportedly exploring a future screenless wearable. By Priyanka Shaw Technology Correspondent, TelecomTalk Published on Oct 3, 2026 3:57pm IST Highlights. * WHOOP, Fitbit, Garmin, Amazfit, Noise and Pebble now compete across different price segments. * Fitbit Air brings Google's Gemini-powered Health Coach to India's screenless tracker market. * Apple currently offers Apple Watch rather than a screenless fitness band, although reports suggest it is exploring the category.

Gizmodo

Sep 30th, 2026

Qalo's screenless health tracker has a Smart Ring companion, too.

Qalo's screenless health tracker has a Smart Ring companion, too. Qalo's new subscription-free fitness SL-1 Smart Band works on its own as a Whoop competitor but is even better when paired with the company's smart ring. Reading time 2 minutes Qalo, maker of a subscription-free smart ring competitor to Oura, apparently has Whoop in its crosshairs, too. The company just announced the SL-1 Smart Band, a new screenless wearable device for your wrist that tracks all the same health data as the company's SR-2 Smart Ring, allowing you to seamlessly switch between them depending on the scenario. The strategy is an increasingly common one in a wearable space where capturing as much data as possible is the goal, and Qalo makes it more compelling by being relatively affordable. The SL-1 is a small rectangular puck of sensors that looks similar to a Whoop 5.0 or competing devices like the Garmin Cirqa, which can be fitted with a variety of silicone and fabric wristbands. Qalo says the device is water-resistant up to around 30 feet and can last over 12 days on a single charge (qualities that will have to be tested in a review), but if you're drawn to the minimalism of screenless wearables, it seems to fit the bill. More importantly, all of the health tracking basics are covered: The SL-1 can monitor your sleep, movement, blood-oxygen levels, heart rate, heart rate variability, stress, skin temperature, and menstrual cycles, all without a subscription. Qalo combines that data into a daily "Q Score" that gives you a sense of your health that day and also offers things like menstrual prediction and automatic workout detection. The real draw of the SL-1 is how it works with Qalo's SR-2 Smart Ring, though. Both devices contribute data to the same health profile, making it possible to switch which device you're wearing without losing data in the process. Qalo imagines its rings working for most people during the day or as a more comfortable option while you're sleeping, with the SL-1 band being for more intense workouts or activities where you need your hands and fingers free. Samsung has pitched wearing its Galaxy Ring and Galaxy Watch together using the same logic. The lightweight Galaxy Ring works on its own, but it's even more useful as the wearable you turn to when you don't want a large screen on your wrist. Google's Fitbit Air could serve the same purpose for anyone who already owns a Pixel Watch. Qalo might not be able to deliver hardware and software at the level of Samsung or Google, but its devices could still be a good alternative because they're relatively inexpensive. The SL-1 Smart Band and SR-2 Smart Ring each retail for $200, meaning you can purchase them both for around the price of an Apple Watch Series 12. For anyone trying to capture as much data as possible, that could be a lot easier to swallow.

Whoop

Program Manager - Foundation AI

About the job